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Context: Resistance to TSH (RTSH) is an inherited disorder of vari-
able hyposensitivity to TSH. The metabolic consequences can range
from euthyroid hyperthyrotropinemia to severe congenital hypothy-
roidism with thyroid hypoplasia. Although subclinical and mild hy-
pothyroidism fitting the RTSH phenotype is common in the popula-
tion, the role of genetic factors is far from being understood. Only in
rare cases has RTSH been attributed to TSHR or PAX8 gene
mutations.
Objective, Setting, andParticipants: Toward the identification of
novel RTSH genes, we studied five large, unrelated families compris-
ing 102 individuals, 56 of whom were affected.
Results: Inheritance of RTSH in these families followed an autoso-
mal dominant pattern without evidence for incomplete penetrance,
yet expressivity was variable. Considering only fully phenotyped gen-
erations, 64% of the progenywas affected, with a 1:1.4male-to-female
ratio. Of 18 affected individuals tested in the neonatal period, two
were undetected because of borderline results. The thyroid phenotype
was indistinguishable from that observed with PAX8 and TSHR de-
fects. In four families, untreated affected subjects of all ages had
elevated serum thyroglobulin levels, consistent with a defect in the
thyroid follicle cells. Linkage of RTSH to TSHR and PAX8 was ex-
cluded in all five families. For the largest families, we likewise ex-
cluded a contribution of genes previously only associated with syn-
dromic forms of RTSH, namely TITF1, GNAS, and FOXE1.
Conclusions: These kindreds represent a distinct etiological entity
of autosomal dominant RTSH. According to the clinical presentation
of these families, genetic causes of mild hyperthyrotropinemia in the
general population may be more common than currently appreciated.
(J Clin Endocrinol Metab 90: 4025–4034, 2005)
PITUITARY TSH IS the principal regulator of growth,differentiation, and function of the thyroid follicular
cells. TSH exerts its effect by binding to the ectodomain of a
specific heptahelical G protein-coupled receptor (TSHR).
TSHR activates the cAMP cascade via the stimulatory gua-
nine nucleotide binding protein (Gs) and, at higher concen-
trations of TSH, also throughGq, thephospholipaseCpathway.
Resistance to the action of TSH (RTSH) is an inherited
condition of variable hyposensitivity to a biologically active
TSH molecule. RTSH was first recognized as a clinical entity
in patientswith congenital hypothyroidism by Stanbury et al.
(1) and subsequently described in several similar cases (2–4).
The clinical hallmarks are: 1) normal to low levels of free
thyroid hormones (TH), depending on the degree of TSH
hyposensitivity; 2) elevated serum levels of biologically ac-
tive TSH; and 3) presence of a normal-sized or hypoplastic
eutopic thyroid gland despite high TSH concentrations (5).
The most common cause of elevated TSH with normal free
TH levels is early-stage autoimmune thyroid disease. These
individuals are distinguished from subjects with RTSH by
1) postnatal onset of abnormalities, 2) presence of thyroid
autoantibodies, and 3) often enlarged thyroid gland.
At the molecular level, RTSH can arise from the inability
to receive the TSH signal or to transmit the TSHR-originated
signals to the genes controlling thyroid cell activity and pro-
liferation. TSHR gene mutations, first found to be the cause
of RTSH in congenitally hypothyroid hyt/hyt mice, have
been identified in over a dozen human families (reviewed in
Ref. 5). In these cases, RTSH is inherited in a recessive fash-
ion. Heterozygotes for one defective allele are usually eu-
thyroid but may have mild hyperthyrotropinemia (6, 7).
TSHR mutations, however, account for only a minority of
cases with RTSH (7, 8).
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Inability of thyroid tissue to adequately respond to the
TSHR-generated signal is also the common feature of the few
reported mutations in PAX8 and TITF1 (Nkx-2.1), transcrip-
tion factors regulating the expression of thyroid-specific
genes including TSHR. Their thyroid phenotype is compa-
rable to that found in TSHRmutations, with variable severity
even within the same family (reviewed in Ref. 9).
We previously reported two small families with mild
RTSH not genetically linked to TSHR, suggesting locus het-
erogeneity (10). Furthermore, the pattern of inheritance was
compatible with a dominant mode of transmission. Themost
powerful approach for gene mapping in dominant, Mende-
lian inherited diseases is parametric linkage analysis of ex-
tended multigenerational families. The latter have proven to
be an invaluable resource in elucidating pathophysiological
pathways in other genetically heterogenous disorders, such
as familial lipodystrophy (11), and those seemingly complex
or polygenic in their sporadic forms, such as non-insulin-
dependent diabetes (12). We report the clinical and genetic
investigation of five multigenerational kindreds, two of
which have individually enough predictive power to detect
genome-wide significant linkage.
Subjects and Methods
Diagnostic criteria and assignment of affection status
Families were evaluated with the aim of collecting multigenerational
pedigrees with dominantly inherited RTSH, amenable for eventual ge-
nome-wide screen. Subjects live in the United States (families 25 and 30),
Israel (family 25), France (family 24), and Canada (families 26 and 35).
No genealogical link was found between the five kindreds. The studies
were approved by the Institutional Review Board of the University of
Chicago and all other participating institutions, and written informed
consent was obtained from all participating subjects. The index cases are
presented below, together with pertinent information on other family
members. Minimal diagnostic tests in all subjects included measure-
ments of serum TSH and either free T4 (FT4) or FT4 index. For subjects
on l-T4 replacement, a definitive affection status could be assigned based
on records of pretreatment TSH levels or its increase after temporary
interruption of hormone treatment. Otherwise, these individuals are
marked as presumptive affected (gray filled symbols in the pedigrees) and,
for the purpose of linkage analysis, assigned unknown or positive af-
fection status depending on the absence or presence of affected progeny,
respectively. The presence of autoantibodies to thyroid peroxidase, thy-
roglobulin (TG), or TSHR (TSHR-binding Igs) was excluded for all
affected subjects, except for those with positive neonatal TSH screening,
which were not all routinely tested for autoantibodies. Apart from
subject III-9 of family 25, who reportedly had goiter on clinical exam-
ination (13), and I-2 of family 30 with large multinodular goiter of
unknown etiology, all affected subjects had normal-sized or hypoplastic
thyroid glands of normal shape and in normal position. Subjects are
identified in the text by generation number and chronological order of
birth.
Family 24 (Fig. 1)
The proposita (I-8) was suspected of being acromegalic or hypothy-
roid because of coarse facial features at age 57 yr. She had a high serum
TSH of 14.5 mU/liter with normal levels of FT4, FT3, and GH (0.3
g/liter). Pituitary glycoprotein hormone -subunit level was 1.4 g/
liter (molar ratio of -subunit to TSH of 0.9; normal,1). TSH increased
to 56mU/liter 15 min after the administration of 200 g TRH iv. A small
thyroid gland with small cystic nodules was found on ultrasound. Mag-
netic resonance imaging showed a normal pituitary gland and stalk.
One of her daughters (II-1) had thyroidectomy at the age of 30 yr for
a benign thyroid nodule and has been on l-T4 replacement ever since.
Before thyroidectomy, but reportedly already on l-T4 therapy, serum
TSH was 16.6 mU/liter with FT4 of 3.2 pmol/liter (normal, 7–17). The
inherited nature of the disorder was not recognized until the realization
that three hyperthyrotropinemic children of the last generation (III-1,
III-4, and III-8) were cousins. All three had high TSH levels on neonatal
screening, but total T4 levels were at the lower limit of normal. Thyroid
scans showed normally located and appearing glands.
Subject III-3 had delayedmental development andwas found to have
mild hyperthyrotropinemia on separate occasions at the age of 7 yr
(mean TSH of 7 mU/liter). Importantly, TSH at neonatal screening was
not reported as abnormal. FT4 concentration and thyroidal radioiodide
uptake (RAIU) were within the normal range.
Blood samples were subsequently obtained from 16 additional mem-
bers of the family originally from the Hainaut Francais region of north-
ern France. Seven were hyperthyrotropinemic, but only one (II-2) had
symptoms of hypothyroidism consisting of hair loss, asthenia, and cold
intolerance. Pertinent information included a low normal thyroid vol-
ume for age on ultrasound in the proposita’s other daughters (II-2, II-3,
and II-4), all of whom had one or two small thyroid nodules. Except for
I-4, I-5, and I-11, who were first tested after initiation of this study, all
affected individuals were given replacement doses of l-T4, which
brought the serum TSH levels to normal. Pretreatment TG levels were
above the upper limit of normal in all affected individuals tested but not
the unaffected subjects. A total of 13 affected members in three gener-
ations were identified.
Family 25 (Fig. 2)
Eleven affected subjects of kindred 25 were briefly reported previously
(13). Thepropositus (III-12), born tounrelatedAshkenazi Jews,was referred
at 3.8 yr of age for the investigation and treatment of hypothyroidism. FT4
was 8.0 pmol/liter (normal, 11–26), TSH was 100 mU/liter, and RAIU at
24 hwas 11% (normal, 8–35).Weight andheightwere at the 30thpercentile,
and bone agewas retarded at 1.3 yr. Treatmentwith l-T4was initiated, and
the subject, now age 27 yr, appears healthy.
Thyroid function test results for 37 family members are shown in Fig.
2. For most receiving l-T4, results of tests before or off treatment could
be obtained. None had apparent sequelae of congenital hypothyroidism.
Among the affected adults, except for subjects II-8 and II-11, none had
history, signs, or symptoms of hypothyroidism at time of initial diag-
nosis. Subject II-8 was on l-T4 replacement from the age of 6 yr. The TSH
response to TRH was exaggerated in the three affected adults that were
tested (I-5, II-9, and II-10) but not in the four normal relatives (III-7, III-10,
III-13, and III-14). Thyroid glands were in the normal anatomic position
in the five individuals (II-10, III-5, III-6, III-9, and III-11) on whom
radioiodide scans were performed, but RAIU at 24 h was low, from
3.8–12%.
A total of 17 affected family members, spanning four generations,
were identified. Three other subjects (I-6, II-7, and II-11) were on con-
tinuous l-T4 treatment because of high serum TSH concentrations, but
records of their pretreatment TSH values could not be traced.
Family 26 (Fig. 3)
The propositus (IV-3), born at term, had a high blood TSH (74 mU/
liter) with normal total T4 when screened at 3 d of age. At 16 d of age,
the knee epiphyses were normally ossified, and 99mpertechnetate scan
revealed slightly diminished uptake in a eutopic thyroid gland. Hyper-
thyrotropinemia with normal FT4 was confirmed on a serum sample,
and treatment with l-T4 was started. After stopping treatment for 1
month at the age of 3 yr, serum TSH rose from 0.46 to 25.2 mU/liter
concomitant with a drop of FT4 from 19.4 to 8.4 pmol/liter (normal,
9–27). The thyroid gland was of normal size and echo pattern on ul-
trasound. At 4 yr of age, sensorineural deafness was diagnosed. The
mother (III-4) had taken l-T4 since the age of 14 yr for the treatment of
nongoitrous hypothyroidismwith no detectable thyroid autoantibodies.
Subject IV-1, born at term to a maternal cousin of III-4, had a blood
spot TSH of 66 mU/liter and normal total T4 at 3 d of age. At 16 d, he
had dry skin, a 0.5-cm umbilical hernia, and no ossification of the
proximal tibial epiphyses. 99mPertechnetate scan showed normal uptake
into a eutopic thyroid gland. Treatment with l-T4 was initiated after
confirmation of hyperthyrotropinemia on a serum sample. After dis-
continuation of l-T4 treatment for 1 month at the age of 3 yr, TSH rose
from 0.12 to 10.4 mU/liter with FT4 decreasing from 24.5 to 10.4 pmol/
liter (normal, 9–27). RAIU was 4.7% at 3 h (normal, 2–6). Nine months
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after the birth of IV-1, his mother (III-1) was found to have a TSH of 23
mU/liter with normal FT4 and total T3 concentrations. RAIU was only
5% at 24 h (normal, 10–30). Fine needle aspiration of a single, scinti-
graphically cold nodule yielded benign follicular cells.
Five members from three generations of this French Canadian family,
with Amerindian admixture, were found to have RTSH. Subjects II-5 and
III-4 had been on l-T4 therapy for years, but records of pretreatment TSH
levels were not available. Because II-5 is the mother of III-4, who has an
affected child (IV-3), they are both obligate carriers of the putative genetic
defect.
Family 30 (Fig. 4)
The index case (III-2) was the second child of nonconsanguineous
parents and the product of a term gestation. He had a positive neonatal
TSH screen, confirmed at 2 and 3 wk of age (30 and 21 mU/liter,
respectively), with a normal thyroid gland in size, shape, and position
on 99mpertechnetate scan. l-T4 replacement was initiated. An umbilical
hernia resolved spontaneously at 8 wk of age. There was neither pro-
longed jaundice nor constipation, and his mental and physical devel-
opment proceeded normally. At the age of 5 yr, discontinuation of l-T4
for 1month increased the TSH to 25mU/liter, but FT4 remained normal.
The older brother (III-1) of the propositus also had a positive neonatal
blood TSH screen, which on retesting was normal. He was not treated and
when retested at 8 yr of agewas hyperthyrotropinemicwith normal FT4 on
three separate occasions (mean TSH of 7.4 mU/liter). In contrast, in the
youngerbrother (III-3), hyperthyrotropinemiadetectedbynewbornscreen-
ing was confirmed at 4 wk of age (TSH of 50 mU/liter; normal FT4).
When first seen by one of us, the granduncle of the propositus (I-1)
had been on l-T4 therapy for 2 yr for an approximately 300-g multi-
nodular goiter of unknown etiology. His pretreatment TSH level is
unknown. Serum TG concentration was very high at 700 g/liter, and
repeated fine needle aspirations provided poor cellular material. The
patient declined surgery. One of his two children (II-1) was found to
have a high serum TSH with a normal thyroid gland. Thus, subject I-1
is presumably a carrier of the genetic defect (obligatory affected).
Six members from three generations had the RTSH phenotype. The
ethnic origins of the affected grandmother (I-2) were Danish and other
Caucasians of European ancestry.
Family 35 (Fig. 5)
The proposita (III-4) had a positive newborn TSH screen, confirmed
at 10 d of age (TSH, 45 mU/liter; normal FT4). A
99mpertechnetate scan
FIG. 1. Pedigree of family 24 with hereditary RTSH. The symbols used are explained on the figure. Results of thyroid function tests are aligned
with each symbol, representing a family member. Values outside the normal range are in bold numbers, and those obtained under L-T4 therapy
are in parentheses. When multiple tests were obtained, values were averaged. Subjects were tested for the indicated polymorphic markers
corresponding to five RTSH candidate genes. The haplotypes are also shown below each symbol, and shading is provided to help trace the
inheritance of the different alleles. , Positive neonatal TSH screen (high TSH value).
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showed a eutopic gland with slightly reduced uptake. She was started
on l-T4 therapy, with normalization of serum TSH. The older sister of
the proposita (III-3) also had an abnormal newborn TSH screen of 38
mU/liter and 9.0 mU/liter with a normal FT4 on recall testing. She was
not treated and when tested at 4 yr of age, her serum TSH was high at
6.5 mU/liter with normal free TH. Their father (II-3) had been treated
intermittently with l-T4. When tested by us off-treatment, serum TSH
was 6.2 mU/liter with normal TH levels.
FIG. 2. Pedigree of family 25 with hereditary RTSH. Progeny of I-1 (five subjects) were normal and are not shown. For details, see legend and
key to Fig. 1.
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The family was of Welsh ancestry, living in Canada. A total of seven
affected members in three generations were identified.
Tests of thyroid function
Total and free T4 and T3 and TSH were measured using commercial
automated immunometricmethods. For the studies correlating bioactive
to immunoreactive serum TSH, the latter was determined by a third-
generation chemiluminescence assay (Elecsys 2010; Roche, Indianapolis,
IN). FT4 index was calculated as the product of the serum total T4 and
the normalized resin T4 uptake ratio (14). The RIA for serum TG was,
in most instances, an in-house assay as previously reported (15). Anti-
thyroid antibodies were measured by passive hemagglutination (Fu-
jirebio, Inc., Tokyo, Japan).
Measurement of TSH bioactivity
Bioactivity of serum TSH was determined by measurement of cAMP
generation by serum added to cultured Chinese hamster ovary cells
stably transfected with a human TSHR cDNA. The method was as
FIG. 3. Pedigree of family 26 with hereditary RTSH. For details, see legend and key to Fig. 1.
FIG. 4. Pedigree of family 30 with hereditary RTSH.
TSH screen indicates initial screen/retesting. For de-
tails, see legend and key to Fig. 1.
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described for the measurement of TSH bioactivity in mouse serum (16),
except for the use of human rather thanmouse TSH-deficient serum. The
former was a pool of sera from five subjects, without thyroid autoan-
tibodies, receiving suppressive doses of l-T4. A similar pool of sera with
high TSH was obtained after short-term withdrawal of l-T4 treatment
and used for the construction of a standard curve using as diluent the
TSH-deficient serum pool. Serum samples from five individuals with
postablative hypothyroidism and immunoreactive TSH levels in the
range found in the samples from RTSH subjects served as control.
Results of cAMP measurements were correlated to those of the TSH
immunoassay by linear regression. To calculate the intrinsic TSH bio-
activity, i.e. the ratio of biological activity to amount of immunoreactive
TSH (B/I ratio), the cAMP results were corrected for TSH-independent
cAMP generation by subtracting the y-intercept of the (uncorrected)
standard regression line.
Genotyping
Genomic DNA was extracted from peripheral blood leukocytes of 94
individuals belonging to the five kindreds. The sequences of PCR prim-
ers used for genotyping and mapping information for markers and
candidate genes are listed in supplemental Table 1 (published as sup-
plemental data on The Endocrine Society’s Journals Online web site at
http://jcem.endojournals.org/). Fluorophore-labeled PCR products
were analyzed on ABI377 DNA sequencers with the GENESCAN soft-
ware (PE Applied Biosystems, Foster City, CA).
Linkage analysis
Two-point LOD scores were calculated using the FASTLINK (version
4.1P) (17) version of MLINK from the LINKAGE program package (18).
Multipoint linkage analysis was performed using SIMWALK2 (version
2.91) (19). All individuals of families 24 and 25 included in the linkage
analysis had a definitive phenotype. In families 26, 30, and 35, subjects
presumed to be affected were coded as being of unknown affection
status. Parametric analysis used an autosomal dominant model of in-
heritance with a disease gene frequency of 1:10,000 and a penetrance for
the affected genotype of 95%. Mild RTSH manifests as subclinical hy-
pothyroidism (SH), which is the most common thyroid disorder with
high prevalence in elderly women (20, 21). However, chronic autoim-
mune thyroiditis, the most common etiology of SH, was excluded as
confounding factor in our subjects by the absence of thyroid autoanti-
bodies and characteristic echogenicity on thyroid ultrasound. Idiopathic
SH with negative thyroid autoantibodies occurs in less than 6% of all
cases (22). Based on this information, we defined four liability classes
with phenocopy rates of 0% (females and males 0–17 yr of age at time
of diagnosis), 0.24% (females 18–44 yr of age), 0.48% (females45 yr of
age), and 0.1% (males 18 yr of age). For multipoint linkage analysis,
the intermarker distances were taken from the Marshfield sex-averaged
genetic map (http://research.marshfieldclinic.org/genetics/). Allele
frequencies were estimated from our own genotyping data using the
combined founder genotype data only. The hypothesis of linkage was
rejected when LOD scores were less than 2.0.
Results
Serum TSH bioactivity
To exclude the possibility that the high serum TSH was
caused by amolecule of reduced biological activity, the latter
wasmeasured in an in vitro bioassay by its ability to stimulate
cAMP generation over the level of TSH-deficient serum. A
bivariate plot of the bioassay results and the amount of
immunoreactive TSH determined on the same samples by
RIA fits a linear regression (Fig. 6). The intrinsic TSH bio-
activity (B/I ratio) in serum of subjects with RTSH (from
families 24 and 30) was not significantly different from that
found in serum of patients with high TSH caused by posta-
blative hypothyroidism (95% confidence interval for mean
B/I of 19.6  2.9 vs. 21.6  6.7; P  0.44; two-tailed t test).
Normal TSH bioactivity had already been demonstrated for
several affected members of family 25 using FRTL-5 cells
(13). These results indicate that the defect resides at the level
of the thyroid gland, in its responsiveness to a normal TSH
molecule.
Segregation analysis of RTSH in five multigenerational
kindreds
A total of 102 subjects (48 definitively affected, eight pre-
sumed to be affected, and 46 normal) were studied. Of the
affected subjects, 33 were women and 23 men, a 1.4:1 ratio.
Considering nuclear families with one affected parent and
complete information on the progeny’s phenotype, 34 were
affected and 19 were not. This apparent preponderance of
affected of 64% was not significantly different from the ex-
pected 50% for a dominant Mendelian distribution. Results
of selected thyroid function tests are depicted on the pedi-
FIG. 5. Pedigree of family 35 with hereditary
RTSH. For details, see legend and key to Fig. 1.
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grees (Figs. 1–5), with a more detailed description of the
phenotype presented in Subjects and Methods. In all five fam-
ilies, segregation of the RTSHphenotypewas consistent with
Mendelian inheritance following an autosomal dominant
pattern with high penetrance. There was no evidence of
bilineal inheritance of RTSH and all progeny of unaffected
family members had normal serum TSH levels, arguing
against a high rate of phenocopies or imprinted expression.
In families 30 and 35, the pattern of inheritance could also be
consistent with X-chromosomal dominant inheritance. How-
ever, this mode of transmission typically results in a more
severe phenotype inmales comparedwith females,whichwe
did not observe. In family 26, the defect likely originates from
the male ancestor I-1 (deceased), because I-1 is unaffected.
Therefore, the finding of an affected male (II-4) and an un-
affected female (II-6) in the second generation argues against
X-linked inheritance, favoring autosomal dominant
inheritance.
Affected children born after initiation of national screen-
ing programs generally had a positive test, with two excep-
tions. One was subject III-1 of family 30, found to be hyper-
thyrotropinemic at the age of 8 yr, for whom the recall test
after an initial positive blood screen test was considered
negative. The second was the developmentally delayed sub-
ject III-3 of family 24, for whom results from the neonatal
screen could not be traced but who was found to be hyper-
thyrotropinemic at the age of 7 yr. Thus, RTSH is clearly a
congenital condition in these families. There was no hint
toward incomplete penetrance, phenocopies, or parental im-
printing, because unaffected parents never had affected
progeny.
Linkage analysis of the TSH receptor gene
All three TSHRmarkers were informative for linkage in all
five families, except marker D14S74 in family 35 (for the
complete results of the two-point linkage analysis, see sup-
plemental Table 2, which is published on The Endocrine
Society’s Journals Online web site at http://jcem.endojour-
nals.org/). For each pedigree, inheritance of the inferred
haplotypes was discordant with linkage of RTSH to the
TSHR gene.Multipoint analysis formally excluded the TSHR
locus for all five families (Fig. 7, C and D). The maximum
LOD scores within the three-markers interval comprising
TSHR were 6.37 (0.89 cM qter from D14S74) for family 24;
17.72 and 3.16 (both 1.78 cM qter from D14S74) for fam-
ilies 25 and 26, respectively;2.1 (2.22 cM qter fromD14S74)
for family 30; and 4.50 (at the uninformative marker
D14S74) for family 35.
Linkage analysis of the PAX8 gene
All four PAX8markers were informative for linkage in all
five families, except marker D2S293, which was not infor-
mative in family 24. For each pedigree, the segregation pat-
tern of the inferred haplotypes was inconsistent with linkage
between RTSH and the PAX8 locus. Multipoint analysis of
the four-markers interval containing PAX8 revealed maxi-
mum LOD scores of 3.81, 7.74, 3.30, and 5.15 (all at
D2S293) for families 24, 26, 30, and 35, respectively (Fig. 7, A
and B). The maximum multipoint LOD score for family 25
was18.29 (0.65 cM qter D2S293) (Fig. 7A). Thus, for all five
families, linkage of RTSH to the PAX8 locus has been
excluded.
Linkage analysis of other candidate genes (TITF1, FOXE1,
and GNAS)
For families 24, 25, and 26, two-point LOD scores (at a
recombination fraction   0) for markers within TITF1,
GNAS, and FOXE1 were all less than 2.0 (Table 1). Thus,
under the specified inheritance model, linkage of RTSH to
any of these genes was excluded in the three families tested.
Discussion
We present here the clinical and genetic investigation of
five multigenerational families with RTSH. Segregation of
RTSH in each family followed an autosomal dominant mode
of inheritance with high penetrance consistent with a single
major genetic defect. Affected members had TSH of normal
bioactivity and, in all five kindreds, the TSHR and PAX8
genes were excluded as the source of the defect responsible
for RTSH by linkage analysis, strongly inferring the role of
novel gene(s) in nonsyndromic RTSH.
High penetrance but variable expressivity of RTSH is also
a typical feature of familial PAX8 and TSHR mutations in
other subjects we have investigated. The foregoingmanifests
as thyroid hypoplasia, but not ectopy or agenesis, in themost
severely affected subjects. Because these genes play an im-
portant role in the function of the developed gland,we expect
that sensitive thyroid function tests will likewise generally
reveal abnormalities in carriers of a genetic defect associated
with RTSH. It is to be stressed that this inheritance pattern
is fundamentally different from that in thyroid dysgenesis
because of ectopy or athyreosis, where very low penetrance
rates have been proposed to account for the segregation
FIG. 6. Correlation of TSH bioactivity with immunological reactivity
in serum of patients with RTSH (gray shaded triangles; continuous
regression line) and patients with hyperthyrotropinemia due to pri-
mary hypothyroidism (prim. hypothyroid) (open circles; dotted regres-
sion line). TSH serum bioactivity was measured as amount of cAMP
generated by incubation of CHOcells stably transfectedwith a human
TSHR cDNA and corrected for the cAMP level produced by incubation
with TSH-deficient serum. The immunological amount of TSH in the
same serum samples was determined by a third-generation RIA. The
intrinsic TSH bioactivity is reflected by the B/I ratio.
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pattern in familial clustered cases (23). Because ectopy and
athyreosis have been observed within the same family (24),
arrested migration of the thyroid anlage followed by either
survival or involution of the ectopic tissue is presumably the
common pathogenetic mechanism. Given the predominance
of apparently sporadic cases, these forms of dysgenesis may
involve threshold and epistatic effects of genes crucial for
migration. The genes involved in ectopy/athyreosis, in con-
trast to those implicated in RTSH/hypoplasia, may not be
crucial for function of the migrated gland in nonpenetrant
carriers of the defect. This is supported by the observation
that, in familial clustered cases of thyroid ectopy and/or
athyreosis, all presumptive carriers of the genetic defect with
orthotopic gland had normal thyroid function, although
some of thosemay haveminor developmental thyroid anom-
alies (23).
In all five families, affected individuals screened at birth
had elevated TSH levels. In two subjects, the newborn TSH
screen was not judged to be abnormal based on the results
of recall testing. Nevertheless, they were found to be hyper-
thyrotropinemic later in childhood. It should be noted that
60–70% of newborns with elevated screening TSH are clas-
sified as false positives after short-range recall examination,
but half of them are found to be subclinically hypothyroid
when followed-up at 16–44 months of age (25). Thus, ele-
vated TSH at screening may be a clinically relevant marker
for mild persistent thyroid abnormalities.
The metabolic abnormalities of RTSH in our families are
FIG. 7. Multipoint linkage exclusion maps for the PAX8 (A and B) and TSHR (C and D) loci. The criterion for exclusion of linkage (LOD of2.0)
is indicated by the dotted lines.
TABLE 1. Two-point parametric LOD scores for linkage between RTSH and TITF1, GNAS, and FOXE1 markers for a range of
recombination fractions (0.0    0.4)
Marker name (locus) Familyno.

0.0 0.05 0.1 0.2 0.3 0.4
AFM214YG5 (TITF1) 24 11.10 2.14 1.22 0.43 0.10 0.01
25 3.09 0.04 0.37 0.63 0.58 0.36
26 4.26 0.61 0.36 0.15 0.06 0.01
rs11468197 (GNAS) 24 3.07 0.72 0.44 0.19 0.08 0.02
25 7.46 3.64 2.47 1.28 0.63 0.23
26 4.46 0.76 0.47 0.21 0.08 0.02
(Ala)n(FOXE1) 24 5.34 1.56 1.07 0.55 0.26 0.09
25 5.72 1.18 0.65 0.20 0.02 0.04
26 4.38 0.46 0.24 0.09 0.05 0.03
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reminiscent of those caused by TSHR or PAX8mutations, yet
one observation deserves mentioning: TG levels were above
the upper limit of normal in 14 of 20 affected subjects tested,
but only in one of 27 unaffected. The association of elevated
TG levels with the RTSH phenotype becomes even more
striking if we exclude family 30, in which only one of six
affected subjects had a high TG level. In patients with PAX8
or TSHR mutations, serum TG levels are variable, from un-
detectable to normal. In three neonates with severely hyp-
oplastic thyroid glands secondary to biallelic TSHR muta-
tions, TG levels were in the normal range, possibly
disproportionately high relative to thyroid size (26–28). Fol-
low-up TG levels were normal and did not increase with the
rise in TSHwhen l-T4 treatment was interrupted. It has been
speculated that incomplete polarization of thyrocytes,
misrouting of TG as a result of aggregation of mutant TSHR
in the endoplasmic reticulum, or intercellular leakage from
dysplastic folliclesmay account for this phenomenon (26). As
in mice (29, 30), expression of TG in the neonatal period may
also be independent of TSH signaling. In our families, how-
ever, high serum TG levels were documented in infants as
well as adults, suggesting a permanent defect in thyroid
differentiation rather than delayed maturation.
Although only TSHR and PAX8 are established candidate
genes for nonsyndromic RTSH, specific defects in genes im-
plicated in syndromic forms of RTSH (TITF1 and GNAS) or
thyroid-specific transcriptional regulation (FOXE1) could
theoretically cause nonsyndromic RTSH. Such defects, e.g. in
cis-regulatory elements crucial for thyroid-specific expres-
sion, were, however, likewise excluded in the three families
tested by linkage analysis. Numerous genes could be con-
sidered as hypothetical candidates based on their biochem-
ical function, but the complexity of TSH signaling makes a
comprehensive evaluation using a candidate gene approach
daunting. The molecular level at which the genetic defect
impairs positive TSH signaling could be further defined by
biopsies of the patients’ thyroids, which are not only difficult
to obtain from hypoplastic glands but also considered un-
ethical. Other than those excluded by linkage, there are cur-
rently no other known mediators of the TSH response ex-
pected to produce a thyroid-restricted phenotype.
We believe that the role of genetic defects in the etiology
of mild thyroid abnormalities in the general population may
be underestimated for several reasons. First, age-indepen-
dent ethnic differences in the median serum TSH levels, not
explained by the prevalence of autoimmune thyroid disease
or confounding environmental factors (21), is a well known
phenomenon (21, 31). This suggests distinct genetically de-
termined thyroid-pituitary set-points. Second, a significant
proportion of patients with mild hypothyroidism without
detectable autoantibodies does not progress to overt hypo-
thyroidism. Genetic factors have to be considered in this
subset of patients, especially if born before implementation
of newborn screening. Third, although current neonatal
screening protocols are highly efficient in the detection of
congenital hypothyroidism, mild, yet permanent, hyperthy-
rotropinemia is likely to bemissed by screening, as indicated
by follow-up studies of children with false positive or bor-
derline test results (25, 32). This notion is also supported by
the failure of neonatal screening to identify two affected
subjects of our family material. Because the postnatal TSH
surge requires a high TSH cutoff level to maintain specificity
of the screening test, subtle RTSH may go unnoticed in the
neonatal period. Thus, the diagnostic difficulties in new-
borns and the high prevalence of thyroid autoimmunity in
the general population may both obscure the inherited na-
ture of RTSH.
By exclusion of linkage to all genes previously associated
with RTSH, this study provides the most convincing evi-
dence for an unidentified genetic component in isolated
RTSH. RTSH in our families is inherited in an autosomal
dominant fashion and frequently associated with elevated
serum TG levels. Identification of the underlying genetic
defect(s) should provide fresh insights into pathways im-
portant for development and normal physiological function
of the thyroid gland. Via epigenetic mechanisms, the very
gene(s) responsible for familial RTSH may well be involved
in the etiology of seemingly sporadic forms of RTSH and
thyroid hypoplasia. Two of the kindreds reported here, fam-
ilies 24 and 25, individually have enough power to detect
linkage that genome-wide screens have been undertaken in
an effort to map the culprit gene(s).
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